bomedemstat
bomedemstat: sourced relationships with 1 company · 9 clinical trials tracked.
bomedemstat evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
How could bomedemstat → IMGO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Imago BioSciences, Inc. (IMGO) Polycythemia Vera; Essential Thrombocythemia | Phase 2 |
Clinical Trial Registry Records (9)
Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
Primary endpoint: SVR35 at Week 24
A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea
Primary endpoint: Clinicohematologic Response (CHR) Rate
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
Primary endpoint: Durable Clinicohematologic Response (DCHR) Rate
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Primary endpoint: Percentage of participants with one or more adverse events (AEs)
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea
Primary endpoint: Durable Clinicohematologic Response (DCHR) Rate
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)
Primary endpoint: Number of Participants With Adverse Events (AEs)
VenBom: A Phase 1 Study of Bomedemstat (IMG-7289), a Novel Inhibitor of Lysine-Specific Demethylase 1 (LSD1), in Combination With Venetoclax in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Primary endpoint: Incidence of Treatment-Emergent Toxicity
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
Primary endpoint: Percentage of Participants Who Experience an Adverse Event (AE)
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
Primary endpoint: Number of Participants Who Experienced an Adverse Event (AE)
Frequently asked questions
Which companies have sourced relationships with bomedemstat?
bomedemstat has dated SEC/FDA relationship records for Imago BioSciences, Inc..
How many clinical trials involve bomedemstat?
BioSniper tracks 9 clinical trials involving bomedemstat.